14 Februar 2012

Investments in Biotech

The Buy-Side View for 2012

What’s the forecast for biotech in 2012? Do investors think it is a good time to invest in biotechnology? Are they interested in taking on early stage companies?

At the BIO CEO & Investor Conference opening plenary, the BIO Industry Analysis team released results from their Investor Perception Study and, afterwards, a panel of portfolio managers and senior buy-side analysts fielded a range of question about the challenges and opportunities facing the industry. David Gluckman, M.D., managing director and co-head of North American Life Sciences, moderated the panel that included: